Songjiang Ma Sells 2,000 Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma sold 2,000 shares of the business’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $12.40, for a total transaction of $24,800.00. Following the completion of the sale, the president now owns 2,920,467 shares in the company, valued at $36,213,790.80. This represents a 0.07 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Songjiang Ma also recently made the following trade(s):

• On Monday, December 30th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.50, for a total transaction of $25,000.00.
• On Thursday, December 26th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.70, for a total transaction of $25,400.00.
• On Monday, December 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.27, for a total transaction of $24,540.00.
• On Thursday, December 19th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.82, for a total transaction of $21,640.00.
• On Tuesday, December 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.05, for a total transaction of $22,100.00.

Gyre Therapeutics Trading Down 9.8 %

GYRE stock traded down $1.06 during mid-day trading on Monday, reaching $9.73. 313,303 shares of the stock traded hands, compared to its average volume of 196,608. Gyre Therapeutics, Inc. has a one year low of $8.26 and a one year high of $27.10. The business has a 50-day moving average price of $12.49 and a two-hundred day moving average price of $12.69.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of GYRE. Bank of New York Mellon Corp bought a new position in Gyre Therapeutics during the second quarter valued at $218,000. Rhumbline Advisers bought a new position in Gyre Therapeutics during the second quarter valued at $123,000. WINTON GROUP Ltd purchased a new stake in shares of Gyre Therapeutics during the second quarter valued at $220,000. Renaissance Technologies LLC purchased a new stake in shares of Gyre Therapeutics during the second quarter valued at $166,000. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Gyre Therapeutics by 392.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company’s stock valued at $1,425,000 after purchasing an additional 90,557 shares during the period. Institutional investors own 23.99% of the company’s stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.